Trials / Completed
CompletedNCT06305702
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
Multicenter Real-world Clinical Study of Inetetamab-based Therapy in HER2-positive Metastatic Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- Liaoning Cancer Hospital & Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | inetetamab | 8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-12-31
- Completion
- 2024-01-31
- First posted
- 2024-03-12
- Last updated
- 2024-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06305702. Inclusion in this directory is not an endorsement.